IBIO touts long-acting antibody pipeline for obesity and muscle loss
IBIO highlighted a pipeline of long-acting antibodies aimed at obesity and related cardiometabolic disease, emphasizing quality weight loss and muscle preservation. Key assets cited include an Activin E antibody and a myostatin-targeting molecule.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.